Abstract:BACKGROUND:FGF21 is a promising intervention therapy for metabolic diseases as fatty liver, obesity and diabetes. Recent results suggest that FGF21 is highly expressed in hepatocytes under metabolic stress caused by starvation, hepatosteatosis, obesity and diabetes. Hepatic FGF21 elicits metabolic benefits by targeting adipocytes of the peripheral adipose tissue through the transmembrane FGFR1-KLB complex. Ablation of adipose FGFR1 resulted in increased hepatosteatosis under starvation conditions and abrogation of the anti-obesogenic action of FGF21. These results indicate that FGF21 may be a stress responsive hepatokine that targets adipocytes and adipose tissue for alleviating the damaging effects of stress on the liver. However, it is unclear whether hepatic induction of FGF21 is limited to only metabolic stress, or to a more general hepatic stress resulting from liver pathogenesis and injury.METHODS:In this survey-based study, we examine the nature of hepatic FGF21 activation in liver tissues and tissue sections from several mouse liver disease models and human patients, by quantitative PCR, immunohistochemistry, protein chemistry, and reporter and CHIP assays. The liver diseases include genetic and chemical-induced HCC, liver injury and regeneration, cirrhosis, and other types of liver diseases.RESULTS:We found that mouse FGF21 is induced in response to chemical (DEN treatment) and genetic-induced hepatocarcinogenesis (disruptions in LKB1, p53, MST1/2, SAV1 and PTEN). It is also induced in response to loss of liver mass due to partial hepatectomy followed by regeneration. The induction of FGF21 expression is potentially under the control of stress responsive transcription factors p53 and STAT3. Serum FGF21 levels correlate with FGF21 expression in hepatocytes. In patients with hepatitis, fatty degeneration, cirrhosis and liver tumors, FGF21 levels in hepatocytes or phenotypically normal hepatocytes are invariably elevated compared to normal health subjects.CONCLUSION:FGF21 is an inducible hepatokine and could be a biomarker for normal hepatocyte function. Activation of its expression is a response of functional hepatocytes to a broad spectrum of pathological changes that impose both cellular and metabolic stress on the liver. Taken together with our recent data, we suggest that hepatic FGF21 is a general stress responsive factor that targets adipose tissue for normalizing local and systemic metabolic parameters while alleviating the overload and damaging effects imposed by the pathogenic stress on the liver. This study therefore provides a rationale for clinical biomarker studies in humans.

Hypoxia-Induced Lipid Accumulation Involves A Hif-Alpha Independent, Oxidative Stress-Mediated Regulation Of Fgf-21 In Hepg2 Cells

Hypoxia-Induced Adipose Lipolysis Requires Fibroblast Growth Factor 21.

HIF-1α and HIF-2α are critically involved in hypoxia-induced lipid accumulation in hepatocytes through reducing PGC-1α-mediated fatty acid β-oxidation.

Cobalt Chloride Induces the Reduction of Fibroblast Growth Factor 21 in Caco‐2 Cells Through HIF and PPAR‐α and –γ Pathway

The Link Between Fibroblast Growth Factor 21 and Sterol Regulatory Element Binding Protein 1c During Lipogenesis in Hepatocytes

FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity.

Activation of Liver FGF21 in Hepatocarcinogenesis and During Hepatic Stress

Control of Lipid Metabolism by Adipocyte FGFR1-mediated Adipohepatic Communication During Hepatic Stress

Fibroblast Growth Factor 21 is Regulated by the IRE1α-XBP1 Branch of the Unfolded Protein Response and Counteracts Endoplasmic Reticulum Stress-Induced Hepatic Steatosis.

FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk

[FGF21 inhibits lipid accumulation and inflammation induced by palmitate in human hepatocytes via SIRT1 pathway].

Lipotoxic Effect of P21 on Free Fatty Acid-Induced Steatosis in L02 Cells

Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice

Silencing of FGF‐21 Expression Promotes Hepatic Gluconeogenesis and Glycogenolysis by Regulation of the STAT3–SOCS3 Signal

Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic β-cell dysfunction via regulation of AMPK signaling and lipid metabolism.

Hypoxia Induces Dysregulation of Lipid Metabolism in Hepg2 Cells Via Activation of Hif-2 Alpha

Fibroblast Growth Factor 21 Suppresses Adipogenesis in Pig Intramuscular Fat Cells

FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response

Α‐lipoic Acid Up‐regulates Gene Expression but Reduces Protein Levels of Fibroblast Growth Factor 21 in HepG2 Cells

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice